about
CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor ActivityTwenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyAdoptive T-cell therapy for LeukemiaTargeting the tumor vasculature to enhance T cell activityCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyEngineering T Cells to Functionally Cure HIV-1 InfectionConstruction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells.New option for the initial management of metastatic pancreatic cancer?Versatile strategy for controlling the specificity and activity of engineered T cells.Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.Engineered T cells for cancer therapy.Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activityHostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologistsNovel agents for the treatment of childhood acute leukemia.Chemical tools to monitor and manipulate the adaptive immune system.De novo generation of HSCs from somatic and pluripotent stem cell sources.Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications.Building better monoclonal antibody-based therapeutics.Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyReceptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Macrophages are critical effectors of antibody therapies for cancerA fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Chicken scFvs with an Artificial Cysteine for Site-Directed ConjugationHIV-specific CD8⁺ T cells and HIV eradicationCostimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells.Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axisInterleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.Costimulatory and Coinhibitory Receptor Pathways in Infectious DiseaseThe TNF Receptor Superfamily in Co-stimulating and Co-inhibitory ResponsesConstruction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cellsChimeric antigen receptor-modified T cells strike back.A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.
P2860
Q26782520-32D71BC8-E7F5-4E3F-91F1-2B79124A1610Q26782649-D19006FB-6F7C-4D80-81E7-84F3D162BC05Q26784480-2FFFA09F-96BF-40A9-8B35-4E8CE46F8D1DQ26799357-B9844D77-0ACC-4D79-9F2E-E8BD0519A9DEQ26823515-B6E5BDD7-A40C-4D69-A643-3F7613F15A8DQ27006934-F29A3146-44BC-4068-AD74-2288E9F5E85AQ27026329-10142CEC-2A7B-4CFC-AB0A-4F9B33285E58Q28084879-8F55EC58-607C-4231-AEFF-E3C67CC3C9DDQ28085397-C0DC5FE6-BCCE-443F-978B-18F82682E01EQ28086801-F3F6CFED-1D79-4FF3-A896-A78EDB5285B3Q33598920-988A4EE3-B38F-4953-8D37-88B1216FEFB7Q34000969-085D6076-0955-4A90-91B6-A0FC4D5F6640Q34045831-026F3867-BC90-4736-94FC-08FF3A0A3351Q34046041-A7E0F169-2541-4735-BF67-61479C66ECA5Q34080368-A24B9D71-73FB-43D0-8CF7-48A27789BA16Q34232877-9B269965-F5C7-45FE-AF3C-F9C703CE1918Q34765959-75B921A5-233E-4DA5-99E1-3E3D03846221Q35090797-54782C6D-91C4-427A-9DA6-0656C1005AACQ35192790-35EEF66A-2B79-40D3-908C-E7878811829AQ35264291-43B2B09C-5845-43D2-AEDE-1D54701724FDQ35533599-FFB5FB15-5AEA-4CF1-B9C4-7612FD5DF05CQ35711209-B6D43327-DB6C-4C1B-B723-69109F5C7DF5Q35817552-D3574572-C41E-48E8-9139-8841C7193EA5Q35857352-DBFA55F2-BE4E-4F4D-8257-56733F5078FDQ36047074-1EDD5EB9-7C18-47A8-913A-A970A4112524Q36110355-A3F94423-05E4-4BD8-AC50-5339A9AD0B75Q36213288-93498523-CCFD-4F16-B659-14FA1DFB43A1Q36356392-EE18F897-CCF0-4AB1-9AC4-2792629A9DAFQ36463396-7ABBA01C-F742-4DCD-A055-34AF22847B25Q36515071-5FFCEE0B-30AC-4419-B073-3521538BFC29Q36519394-2AF5CE1A-717D-4FA5-9E60-D9827820CB16Q36607439-EF8227C0-6FE2-41BA-8D55-2548CDB14B67Q36721440-4963A80B-5C1B-4B71-B245-A051900991F2Q36746004-E80B34C2-7ECC-4DD3-B5E0-EDD72A5F6949Q36919711-C816A4DE-71DF-414D-8585-02F8CD06FB25Q36940326-7BFB16C6-228E-4FAF-A421-FA06C1F440CAQ36963057-2B3FCCFC-FBBD-4116-B329-713798BED6CBQ37040370-6C9C2438-BEB6-419B-BA41-55158D133D85Q37317390-6DA990CE-B0A3-45AB-800D-4C0058AAE99DQ37370230-6427E029-1C6B-4B9E-B85E-534897B035E0
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Chimeric antigen receptor therapy for cancer
@ast
Chimeric antigen receptor therapy for cancer
@en
Chimeric antigen receptor therapy for cancer
@nl
type
label
Chimeric antigen receptor therapy for cancer
@ast
Chimeric antigen receptor therapy for cancer
@en
Chimeric antigen receptor therapy for cancer
@nl
prefLabel
Chimeric antigen receptor therapy for cancer
@ast
Chimeric antigen receptor therapy for cancer
@en
Chimeric antigen receptor therapy for cancer
@nl
P2093
P2860
P3181
P1476
Chimeric antigen receptor therapy for cancer
@en
P2093
Carl H. June
David L. Porter
David M. Barrett
Nathan Singh
Stephan A. Grupp
P2860
P304
P3181
P356
10.1146/ANNUREV-MED-060512-150254
P407
P577
2014-01-01T00:00:00Z